Document is current

Article History

First Online: 13 May 2026

Competing interests

: A.C. has received speaking fees from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Menarini; research grants from Eli Lilly, Novo Nordisk and Menarini; and is a member of the data-monitoring committee of Boehringer Ingelheim. J.L.B. is an advisory board member for Novo Nordisk (all fees paid to the institution); is a representative of EASO on a Regeneron council (volunteer, no fees); has received speaker honoraria for participation in sponsored scientific sessions (all fees paid to the institution); and is the president-elect of EASO. A.B. has received payment of honoraria from AstraZeneca, Servier, Novo Nordisk, Eli Lilly and Novartis as speaker and/or member of advisory boards; is secretary of the Croatian Society of Obesity EASO ECN board (middle region) EASO COMs Working Group. L.B. has received payment of honoraria from Amgen, Boehringer Ingelheim, Bruno Farmaceutici, Eli Lilly, Novo Nordisk, Pfizer, Recordati, Regeneron and Roche; has received speaker fees or educational activities from Pronokal and Rhythm Pharmaceuticals; is vice president of the southern region of EASO; and is a member of the Standing Expert Panel for the endocrine-metabolic area of the National Guidelines System of the Italian Institute of Health (Istituto Superiore di Sanità). D.D. has received speaker and advisory board fees from Boehringer-Ingelheim, Eli Lilly, Novo Nordisk and AstraZeneca; and has received research grants from Eli Lilly, Novo Nordisk and Boehringer Ingelheim. L.F. has received speaker and/or advisory fees from Novo Nordisk, Eli Lilly, Zentiva and Stada; and is vice president of the middle region of EASO. G.F. has received payment of honoraria from Eli Lilly, Novo Nordisk, Regeneron, AstraZeneca and Marabou Foundation as a speaker and/or a member of advisory boards; and has received payment of honoraria as member of the OPEN Spain Initiative. G.G. has received a research grant from Novo Nordisk; and has received payment of honoraria as speaker (company educational seminars) from Novo Nordisk and Eli Lilly (all fees paid to the institution). J.G. is a shareholder of Elevate Access, which has received research and educational funding, including from the EASO. P.S. has received payment of honoraria and consulting fees from Boehringer Ingelheim, Chiesi, Novo Nordisk, Eli Lilly, Pfizer and Roche as a member of advisory boards. B.M.-T. has received grants from the EASO New Clinical Investigator Award 2024 and the EFSD Rising Star 2024, both supported by the Novo Nordisk Foundation. M.M. has received speaking fees from AstraZeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Merck, Novo Nordisk, Sanofi and Novartis; and has received research grants from Bristol Myers Squibb. V.Y. was engaged in advisory boards and lectures with Novo Nordisk, Eli Lilly, Rhythm and Regeneron; and is president of the EASO. B.M. has received speaker and/or advisory fees from Novo Nordisk, Eli Lilly, AstraZeneca, Janssen, Pfizer and MSD; has received a research grant from Novo Nordisk; and is a shareholder of Reset Health.